Expert Review of Hematology最新文献_第8页

An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor). regan Burnell-Clarke（委托编辑）对Joshua Richter博士的采访，讲述了他作为linvoseltamab-gcpt研究员的经历。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-06-01 Epub Date: 2026-03-20 DOI: 10.1080/17474086.2026.2647574

Joshua Richter

引用次数: 0

The molecular pathogenesis of Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a scoping review. eb病毒相关b淋巴细胞增生性疾病的分子发病机制：范围综述

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-06-01 Epub Date: 2026-04-19 DOI: 10.1080/17474086.2026.2655963

Johanna Vets, Xenia Haest, Thomas Tousseyn

{"title":"The molecular pathogenesis of Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a scoping review.","authors":"Johanna Vets, Xenia Haest, Thomas Tousseyn","doi":"10.1080/17474086.2026.2655963","DOIUrl":"10.1080/17474086.2026.2655963","url":null,"abstract":"Epstein Barr virus (EBV) latent proteins play a pivotal role in the pathogenesis of EBV-associated lymphoproliferative disorders (EBV LPDs) effectively substituting for oncogenic driver mutations. EBV-related lymphomas are mutationally distinct from their EBV-negative counterpart disease but undergo similar treatment. Advancing therapies for EBV LPDs require a better understanding of the molecular pathogenesis of EBV LPDs. This scoping review summarizes current evidence on the molecular profile in EBV-positive diffuse large B-cell lymphoma (EBV-positive DLBCL, NOS), EBV-positive mucocutaneous ulcer (EBVMCU), DLBCL associated with chronic inflammation (DLBCL-CI), fibrin associated DLBCL (FA-DLBCL), Lymphomatoid granulomatosis (LyG), and classic Hodgkin Lymphoma (cHL). Generally, EBV-positive lymphomas exhibit fewer genomic alterations and less rearrangements in oncogenic driver genes such as BCL2, BCL6, and MYC, compared to their negative counterpart disorders. Also, the mutational landscape of EBV LPDs is delineated by aberrations in NF-kB, JAK-STAT, and NOTCH pathways. Amplification of 9p24.1, causing PD-L1 overexpression, plays a significant role in EBV-positive DLBCL and EBV-positive cHL, whereas EBVMCU, DLBCL-CI, FA-DLBCL, and LyG primarily depend on a (local) immunosuppressive condition. In conclusion, the molecular pathogenesis of EBV LPD is less reliant on driver mutations and instead relies on EBV latent genes and immune evasion; both factors provide promising targets for future therapy.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"623-640"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of systemic mastocytosis with associated hematologic neoplasm: midostaurin and beyond. 与血液学肿瘤相关的全身肥大细胞增多症的治疗：midoin及其他。

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2026-06-01 Epub Date: 2026-04-06 DOI: 10.1080/17474086.2026.2654717

Sona Vardanyan, Håkon Reikvam

引用次数: 0

Reconsidering time from diagnosis to treatment in acute myeloid leukemia: from therapeutic urgency to biologically informed timing. 重新考虑急性髓性白血病从诊断到治疗的时间：从治疗急迫性到生物学知情的时机。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-06-01 Epub Date: 2026-03-31 DOI: 10.1080/17474086.2026.2653588

Matteo Molica, Laura De Fazio, Ferdinando Porretto, Antonino Mulè, Marco Rossi, Massimo Martino, Caterina Alati

{"title":"Reconsidering time from diagnosis to treatment in acute myeloid leukemia: from therapeutic urgency to biologically informed timing.","authors":"Matteo Molica, Laura De Fazio, Ferdinando Porretto, Antonino Mulè, Marco Rossi, Massimo Martino, Caterina Alati","doi":"10.1080/17474086.2026.2653588","DOIUrl":"10.1080/17474086.2026.2653588","url":null,"abstract":"Introduction: Acute myeloid leukemia (AML) has traditionally been considered a medical emergency requiring immediate cytotoxic therapy, a paradigm rooted in the pre-molecular era and high early mortality of untreated disease. However, modern AML management relies on cytogenetic, molecular, and next-generation sequencing (NGS) profiling to guide prognosis, transplant decisions, and targeted therapies, making time from diagnosis to treatment (TDT) a clinically relevant variable.Areas covered: A focused literature review (PubMed/MEDLINE, Embase, Web of Science) shows that short, biologically driven delays to complete molecular diagnostics do not adversely affect survival, including in patients receiving venetoclax-based regimens. Conversely, prolonged system-related delays remain associated with worse outcomes. The impact of TDT is heterogeneous across molecular subgroups, with emerging data suggesting differential sensitivity in IDH1/2- and TP53-mutated AML. In the NGS era, the diagnostic-to-treatment interval should be viewed as an active, biologically informed phase rather than a passive delay.Expert opinion: TDT should be considered a biology-adapted decision rather than a measure of urgency: brief, purposeful delays to refine genomic profiling may optimize treatment selection without compromising outcomes, whereas system-driven delays remain harmful and inequitable.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"601-606"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147573020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-06-01 Epub Date: 2026-04-03 DOI: 10.1080/17474086.2026.2654712

Haiyan Liang, Yang Yang, Lin Pan, Yanni Xie, Yongrong Lai

{"title":"Health-related quality of life and associated factors in Chinese pediatric patients with β-thalassemia major receiving transfusion and iron chelation therapy: a cross-sectional study.","authors":"Haiyan Liang, Yang Yang, Lin Pan, Yanni Xie, Yongrong Lai","doi":"10.1080/17474086.2026.2654712","DOIUrl":"10.1080/17474086.2026.2654712","url":null,"abstract":"Background: This cross-sectional study assessed health-related quality of life (HRQOL) outcomes and the factors affecting HRQOL in Chinese patients with β-thalassemia major (β-TM) receiving transfusion and iron chelation therapy.Research design and methods: The Pediatric Quality of Life Inventory (PedsQL)4.0 Generic Core Scales were administered to 198 patients and 431 heathy controls aged 4-18 years old. The relationship of sociodemographic and clinical factors with HRQOLscores were analyzed using association and linear regression analyses.Results: Compared with healthy peers, patients exhibited significantly lower PedsQL scores across all domains (p < 0.001). Patients with Body Mass Index (BMI) below the 50th percentile (the median BMI for Chinese children and adolescents) exhibited poorer HRQOL scores than those with BMI ator above this threshold in physical functioning (p = 0.034). Iron chelation therapy and pre-transfusion hemoglobin levels exceeding 7.5 g/dL emerged as significant positive predictors of total summary score, while the presence of two comorbidities was identified as significant negative predictors (p = 0.037, p < 0.001 and p = 0.001, respectively).Conclusions: Standardized treatment involving blood transfusion and iron chelation therapy in β-TM patients requires further enhancement. Additionally, improving nutritional status and preventing and treating comorbidities may benefit patients' HRQOL.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"653-659"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transfusion efficacy and adverse events of a restrictive transfusion strategy in patients with acute upper gastrointestinal bleeding. 急性上消化道出血患者限制性输血策略的输血疗效和不良事件。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-06-01 Epub Date: 2026-04-03 DOI: 10.1080/17474086.2026.2654723

Qing Cai, Xinshun Lu, Shiying Liu, Yanjie Cheng, Jun Li

{"title":"Transfusion efficacy and adverse events of a restrictive transfusion strategy in patients with acute upper gastrointestinal bleeding.","authors":"Qing Cai, Xinshun Lu, Shiying Liu, Yanjie Cheng, Jun Li","doi":"10.1080/17474086.2026.2654723","DOIUrl":"10.1080/17474086.2026.2654723","url":null,"abstract":"Background: Acute upper gastrointestinal bleeding (AUGIB) is a life-threatening challenge, necessitating appropriate transfusion strategies to optimize recovery and reduce complications. This study aimed to compare the efficacy and safety of restrictive versus liberal transfusion strategies in patients with AUGIB.Research design and methods: In this prospective, single-center, randomized controlled trial, 110 patients with AUGIB were randomly assigned to a control group (liberal transfusion) or a study group (restrictive transfusion). Outcome measures included transfusion-related indicators, hemostatic outcomes, coagulation parameters, hemorheological indices, and incidence of adverse events and rebleeding.Results: At 72-hour post-transfusion, the study group demonstrated higher fibrinogen and platelet levels, shorter activated partial thromboplastin time, prothrombin time, and thrombin time, elevated hematocrit and plasma viscosity, lower per-capita transfusion volume, hemoglobin, blood lactate, systolic blood pressure, and heart rate, higher 24-hour hemostasis rates, a lower overall incidence of adverse events, and a reduced incidence of rebleeding compared to the control group (all p < 0.05).Conclusions: Compared to liberal transfusion, restrictive transfusion effectively improves short-term hemostasis, coagulation function, and hemorheology while reducing adverse reactions and rebleeding in AUGIB patients. However, the single-center design and absence of long-term follow-up are study limitations.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"661-667"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of the European LeukemiaNet recommendations for chronic myeloid leukemia. 欧洲白血病网推荐慢性髓性白血病的发展。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-06-01 Epub Date: 2026-04-06 DOI: 10.1080/17474086.2026.2654720

Alkim Yolcu, Ibrahim Celalettin Haznedaroglu

{"title":"Evolution of the European LeukemiaNet recommendations for chronic myeloid leukemia.","authors":"Alkim Yolcu, Ibrahim Celalettin Haznedaroglu","doi":"10.1080/17474086.2026.2654720","DOIUrl":"10.1080/17474086.2026.2654720","url":null,"abstract":"Introduction: Chronic myeloid leukemia (CML) management has been revolutionized by tyrosine kinase inhibitors (TKIs), leading to near-normal life expectancy for most patients diagnosed in the chronic phase. The European LeukemiaNet (ELN) recommendations provide the internationally recognized framework for the diagnosis, monitoring, and treatment of CML.Areas covered: This review provides a chronological overview of the evolution of ELN recommendations for CML across five updates (2006, 2009, 2013, 2020, and 2025). Relevant literature published up to January 2026 was identified through a search of PubMed/MEDLINE, using keywords including 'chronic myeloid leukemia,' 'CML,' 'European LeukemiaNet,' 'ELN recommendations,' 'tyrosine kinase inhibitors,' and 'treatment-free remission.'Expert opinion: Over time, ELN recommendations have shifted from cytogenetic to molecular monitoring, incorporated second-generation TKIs, and introduced treatment-free remission as a major therapeutic goal. The latest framework emphasizes personalized CML management by integrating molecular response with patient-specific factors, reflecting the broader evolution of precision medicine in hematology.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"607-621"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety profile of busulfan plus low-dose melphalan (BUMEL) versus high-dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis. busulfan +低剂量melphalan （BUMEL）与高剂量melphalan （MEL200）作为多发性骨髓瘤患者自体造血干细胞移植（auto-HSCT）的调节方案的疗效和安全性：一项系统回顾和荟萃分析。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-06-01 Epub Date: 2026-03-24 DOI: 10.1080/17474086.2026.2649831

Shahzaib Maqbool, Imran Khan, Muhammad Ibrahim, Aye Mon Thida, Muhamamd Salman Faisal, Fatima Faraz, Abat Khan, Moazzam Shahzad, Mohammad Ebad Ur Rehman, Qurat Ul Ain Muhammad, Abdur Rehman

{"title":"Efficacy and safety profile of busulfan plus low-dose melphalan (BUMEL) versus high-dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis.","authors":"Shahzaib Maqbool, Imran Khan, Muhammad Ibrahim, Aye Mon Thida, Muhamamd Salman Faisal, Fatima Faraz, Abat Khan, Moazzam Shahzad, Mohammad Ebad Ur Rehman, Qurat Ul Ain Muhammad, Abdur Rehman","doi":"10.1080/17474086.2026.2649831","DOIUrl":"10.1080/17474086.2026.2649831","url":null,"abstract":"Introduction: The optimal conditioning regimen prior to autologous stem cell transplantation (Auto-HSCT) in multiple myeloma remains uncertain. We conducted a systematic review and meta-analysis to compare the efficacy and safety of busulfan-melphalan (BUMEL) versus high-dose melphalan (HDMEL) conditioning.Methods: A systematic literature search of PubMed, Embase, and the Cochrane Library was performed to from inception to 15 April 2025 to identify comparative studies evaluating BUMEL and HDMEL conditioning prior to Auto-HSCT. Eligible studies reported efficacy and/or safety outcomes. Risk of bias was assessed using standard methodological criteria. Pooled hazard ratios and odds ratios with 95% confidence intervals were calculated using random-effects models.Results: Eleven studies comprising transplant-eligible patients with multiple myeloma were included. BUMEL conditioning was associated with improved progression-free survival compared with HDMEL, favoring BUMEL (HR: 0.83, 95% CI: 0.76-0.89, p < 0.00001), while no definitive overall survival benefit was observed HR: 1.10, 95% CI: 1.00-1.21, p = 0.05). BUMEL was associated with higher rates of mucositis, infections, and hepatic toxicity.Conclusions: BUMEL conditioning offers improved disease control at the cost of increased toxicity, without a clear overall survival advantage. These findings support individualized conditioning selection, particularly in settings where upfront ASCT remains standard practice.Registration: This protocol was registered on PROSPERO with an ID of CRD420261292372.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"641-651"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of mental health conditions among individuals with sickle cell disease in Texas Medicaid. 德克萨斯州医疗补助中镰状细胞病患者精神健康状况的患病率

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-02-27 DOI: 10.1080/17474086.2026.2634988

Blessing I Okoye, Ananya Bhalla, Ayobami A Aiyeolemi, Gloria N Odonkor, Jamie C Barner, Samantha M Catanzano

{"title":"Prevalence of mental health conditions among individuals with sickle cell disease in Texas Medicaid.","authors":"Blessing I Okoye, Ananya Bhalla, Ayobami A Aiyeolemi, Gloria N Odonkor, Jamie C Barner, Samantha M Catanzano","doi":"10.1080/17474086.2026.2634988","DOIUrl":"10.1080/17474086.2026.2634988","url":null,"abstract":"Background: While individuals with sickle cell disease (SCD) experience mental health conditions (MHCs) that may negatively impact health outcomes, studies estimating the prevalence of MHCs in this population are limited.Research design and methods: A retrospective analysis of Texas Medicaid data from 01/01/2016-05/31/2021 included individuals aged 3-63 years with SCD and continuously enrolled for one year. Study objectives were addressed using descriptive and bivariate analyses.Results: Of the 2,878 (mean age = 23.1 ± 14.0) individuals included, 29.9% had at least one MHC. The most common MHCs were substance use disorders (15.4%), depressive disorders (8.4%), anxiety (8.3%), and suicidal ideation (6.1%). While no significant difference in age, those with SCD+MHCs had a significantly higher proportion of males (37.1% vs 27.7%, p < 0.0001). Also, compared to those without MHCs, those with MHCs had a significantly (p < 0.0001) higher mean number and proportion, respectively, of vaso-occlusive crises (5.8 ± 5.8 vs. 1.8 ± 3.1; 82.9% vs. 51.9%), SCD-related complications (3.3 ± 2.3 vs. 1.9 ± 1.8; 92.2% vs. 75.5%), and comorbid medical conditions (1.2 ± 1.2 vs. 0.5 ± 0.9; 65.5% vs. 35.7%).Conclusions: Individuals with SCD+MHCs had poorer health outcomes. Timely screening and treatment of MHCs and incorporating mental health specialists into the care team may improve patient outcomes. Interpretation should consider limitations inherent to claims data.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"555-562"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Longer time to response in hemato-oncological patients with immune thrombocytopenia (ITP): a pilot study. 免疫血小板减少症（ITP）的血液肿瘤患者反应时间较长：一项初步研究。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-03-11 DOI: 10.1080/17474086.2026.2641490

Tessa Hattenhauer, Rebekka Mispelbaum, Peter Brossart, Carmen Kuehn, Annkristin Heine

{"title":"Longer time to response in hemato-oncological patients with immune thrombocytopenia (ITP): a pilot study.","authors":"Tessa Hattenhauer, Rebekka Mispelbaum, Peter Brossart, Carmen Kuehn, Annkristin Heine","doi":"10.1080/17474086.2026.2641490","DOIUrl":"10.1080/17474086.2026.2641490","url":null,"abstract":"Background: Hemato-oncological diseases have been described as a common cause of secondary immune thrombocytopenia (ITP). So far, studies on patients with active hemato-oncological disease and concurrent ITP are limited, making it difficult to provide clear treatment recommendations. Due to the underlying disease and cancer treatment, this patient population is especially vulnerable.Research design and methods: This retrospective, single-center pilot study investigated treatment response and time-to-treatment response in patients with newly diagnosed ITP, comparing those with active hemato-oncological disease, those in remission after malignancy, to those without any underlying malignancy.Results: Comparable response rates to ITP treatment were observed across these groups, including the achievement of platelet counts above 30 G/L and complete response (platelet counts ≥100 G/L). However, patients with an active hematologic-oncological malignancy exhibited a significantly longer time to platelet recovery after initiating steroid therapy.Conclusion: Our preliminary data suggest that standard treatment recommendations for primary ITP may be effective in patients with an active hematologic - oncologic malignancy. However, therapy responses could be significantly delayed, warranting closer monitoring. Given the pilot nature of this study and the limited sample size, these findings should be considered hypothesis-generating and require confirmation in larger studies.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"547-553"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0